Who are Macugen (Pegaptanib Sodium)'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/macugen-pegaptanib-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Macugen (Pegaptanib Sodium) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Macugen (Pegaptanib Sodium) (Macugen (Pegaptanib Sodium)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor / Aptamer. Area: Ophthalmology.

marketed VEGF inhibitor / Aptamer VEGF165 (Vascular Endothelial Growth Factor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Macugen (Pegaptanib Sodium) (Macugen (Pegaptanib Sodium)) — Retina Institute of Hawaii. Pegaptanib is an aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Macugen (Pegaptanib Sodium) TARGET	Macugen (Pegaptanib Sodium)	Retina Institute of Hawaii	marketed	VEGF inhibitor / Aptamer	VEGF165 (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor / Aptamer class)

Retina Institute of Hawaii · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Macugen (Pegaptanib Sodium) — Competitive Intelligence Brief. https://druglandscape.com/ci/macugen-pegaptanib-sodium. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing